2024
Risk prediction for clonal cytopenia: multicenter real-world evidence
Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan A, Bewersdorf J, Mendez L, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg H, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner A, Carraway H, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik M, Malcovati L, Savona M, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood 2024, 144: 2033-2044. PMID: 38996210, PMCID: PMC11561536, DOI: 10.1182/blood.2024024756.Peer-Reviewed Original ResearchMyeloid neoplasmsIncidence of MNClonal cytopeniaCumulative incidencePlatelet count <High-risk mutationsCox proportional hazards modelsVariant allele fractionProportional hazards modelClinical trial designCCUS patientsStratify patientsGray's testC-indexDisease entityRisk groupsCytopeniasAllele fractionSomatic mutationsRisk factorsHigh riskNatural historyRisk scoreHazards modelPatientsCentral Venous Catheter Consideration in Pediatric Oncology: A Systematic Review and Meta-analysis From the American Pediatric Surgical Association Cancer Committee
Christison-Lagay E, Brown E, Bruny J, Funaro M, Glick R, Dasgupta R, Grant C, Engwall-Gill A, Lautz T, Rothstein D, Walther A, Ehrlich P, Aldrink J, Rodeberg D, Baertschiger R. Central Venous Catheter Consideration in Pediatric Oncology: A Systematic Review and Meta-analysis From the American Pediatric Surgical Association Cancer Committee. Journal Of Pediatric Surgery 2024, 59: 1427-1443. PMID: 38637207, DOI: 10.1016/j.jpedsurg.2024.03.047.Peer-Reviewed Original ResearchCentral venous catheterIncreased risk of complicationsAbsolute neutrophil countRisk of complicationsIncreased riskCatheter placementCatheter compositionIncreased risk of hematomaTunneled central venous cathetersPlatelet count <Risk of hematomaMeta-analysisIncidence of complicationsLimited evidenceModern oncology practiceEnglish-language articlesCatheter salvageLock therapyNeutropenic patientsCatheter removalBloodstream infectionsTunneled cathetersPlatelet countNo significant differenceVenous catheters
2023
A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Bewersdorf J, Derkach A, Masarova L, Pemmaraju N, Stein E, Mauro M, Rampal R, Bose P. A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood 2023, 142: 6440. DOI: 10.1182/blood-2023-174322.Peer-Reviewed Original ResearchDuration of responseMaximum tolerated doseDose of ruxolitinibCDK4/6 inhibitorsStable doseTolerated doseHormone receptor-positive metastatic breast cancerRisk of progression to acute myeloid leukemiaSymptom scoresPhase I dose-escalation trialProgression to acute myeloid leukemiaTreatment of hormone receptor-positive metastatic breast cancerAbsolute neutrophil count <Cancer CenterCombination of CDK4/6 inhibitorsUS FDAMemorial Sloan Kettering Cancer CenterGrade 1 diarrheaMedian overall survivalPre-study doseDose-limiting toxicityMD Anderson Cancer CenterBone marrow fibrosisNeutrophil count <Platelet count <
2021
Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score
Hwang J, Park S, Lee S, Lee B, Lee M, Jeong G, Kim M, Kim J, Koyanagi A, Jacob L, Jung Y, Song J, Yon D, Shin J, Smith L. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score. European Heart Journal 2021, 42: 4053-4063. PMID: 34545400, PMCID: PMC8500026, DOI: 10.1093/eurheartj/ehab592.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisChAdOx1 nCoV-19 vaccinePresence of intracerebral haemorrhageThrombocytopenia syndromeIntracerebral haemorrhagePresence of cerebral venous thrombosisHigher risk of adverse outcomesPlatelet count <Risk of adverse outcomesNon-heparin anticoagulantsOutcome of thrombosisPredictors of mortalityCOVID-19 vaccine administrationAssociated with deathAssociated with mortalityTTS patientsIntravenous immunoglobulinPrognostic factorsThrombotic thrombocytopeniaClinical presentationPlatelet countCase seriesTreatment modalitiesVenous thrombosisCase report
2014
Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non–ST-segment elevation acute coronary syndrome
Vora A, Chenier M, Schulte P, Goodman S, Peterson E, Pieper K, Jolicoeur M, Mahaffey K, White H, Wang T. Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non–ST-segment elevation acute coronary syndrome. American Heart Journal 2014, 168: 189-196.e1. PMID: 25066558, DOI: 10.1016/j.ahj.2014.04.010.Peer-Reviewed Original ResearchConceptsDischarge medication useSevere thrombocytopeniaMild thrombocytopeniaAntiplatelet therapyCoronary syndromeNadir platelet count <Associated with increased in-hospital mortalityNon-ST-segment elevation acute coronary syndromeElevation acute coronary syndromeOne-year mortality ratePlatelet count <Associated with increased mortalityNadir platelet countLong-term mortalityLong-term outcomesMedication useAcute coronary syndromeIn-Hospital MortalityThrombocytopenia severityBleeding riskHemorrhagic complicationsPlatelet countAcquired thrombocytopeniaSYNERGY trialThrombocytopenia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply